Posts Tagged ‘Marijuana’
INTERVIEW: Bougainville Ventures $BOG.ca Discusses Farmland to Greenhouse Conversion $CROP.ca $VP.ca NF.ca $MCOA
Tetra Bio-Pharma $TBP.ca Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products $AERO $CBDS $CGRW $APH.ca $GBLX
- Made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market
- Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised
ORLEANS, Ontario, Sept. 24, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market.
Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised. This was the first clinical trial of its kind in evaluating the safety and efficacy of different doses and ratios of cannabis oils versus placebo.  The study included a dose titration phase (gradually bringing patients to the required dose) allowing us to better understand the side effect profile of the oils as well as the development of tolerance to these effects.  Thus far, no other company in the medical cannabis space has undertaken such an exhaustive study to understand the therapeutic benefits and side effects of a cannabis oil-based capsule.
Dr. Chamberland, interim CEO and CSO added, “We continue to deliver on our business model that provides for evidence-based research to support the usage of cannabis-derived products and provide the medical community with the data they have been demanding from this sector. The trial has already provided unique valuable clinical data on both safe and efficacious dose levels of CBD and THC-CBD oils. This data will allow Tetra to advance to the next phase of product development wherein the company is developing products for its commercial partner Genacol Corporation Canada, as well as food supplements for the retail market and finally, our capsules that we intend to use in the treatment of chronic and cancer related pain. Tetra has already established itself as a trailblazer in the natural health product segment with the announcement of our intention to launch a Hemp Energy Drink and we intend to build on that momentum.â€
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP005, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
| Media Contact | |
| Energi PR | |
| Carol Levine | Stephanie Engel |
| 514-288-8500 ext. 226 | 416-425-9143 ext. 209 |
| [email protected] | [email protected] |
AGORACOM Welcomes Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca
WHY BOUGAINVILLE?
- Converting irrigated farmland to greenhouse-equipped farmland
- Bougainville does not “touch the plant†by only providing agricultural infrastructure as a landlord for licensed marijuana growers
- First 10,000 square feet of greenhouse space has been completed
- Ready for occupancy
- Room for expansion
- JV Agreement with Marijuana Company of America (MCOA:OTC)
- MCOA invested $1M in cash
Early estimates show a greenhouse can produce twice the amount of product and at least
less than 50% of the cost compared to warehouse production.
Oroville, Washington
- Construction complete of a 10,000 sq. ft. greenhouse optimized for low-carbon and sustainable operations
- I-502 compliant property ready for tenant-grower occupancy
- 50% + senior water right holder on the main stem of the Eden Valley Aquifer and two supplemental groundwater wells
- Entered into a lease agreement with a Tier 3 I-502 production and processing license holder
- Leadership has local farming knowledge and relationships in this region
- Room for further expansion
Turnkey Growing Facilities
Development Phases
Legalized States – Cannabis legalization is spreading across the Nation.
Industry estimates show $27 billion in infrastructure will be needed to meet a full legal US market and Washington State alone will need $679 million in infrastructure.
Market Overview
- Currently up to 650,000 recreational marijuana users in Washington State, worth approximately $1.5 Billion USD in annual sales.
- Beyond the traditional uses for cannabis, the industry has benefited from edibles and CBD/THC products for medical use.
- Upward trajectory of growth in the U.S. market is positively forecasted for years to come.
I-502 License Holders Current Challenges
Namaste $N.ca Acquires #Findify, a Leading A.I. and Machine Learning Company, to Increase Conversion Rates, Average Order Value, Retention and Referrals $ACB.ca $HIP.ca $WEED.ca $CMED.ca
- Company executed a definitive agreement to acquire all of the issued and outstanding shares of Findify AB
- purchase price of US $12,000,000 in a combination of cash and common shares of the Company
- Findify is a global leader in A.I. powered e-commerce personalization, delivering solutions such as personalized search, recommendations, and advanced data analytics
VANCOUVER, British Columbia, May 02, 2018 – Namaste Technologies Inc. (“Namaste†or the “Companyâ€) (TSX-V:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that on May 1, 2018 the Company executed a definitive agreement to acquire (the “Acquisitionâ€) all of the issued and outstanding shares of Findify AB (a Swedish corporation, “Findifyâ€), for a purchase price of US $12,000,000 in a combination of cash and common shares of the Company. Findify is a global leader in A.I. powered e-commerce personalization, delivering solutions such as personalized search, recommendations, and advanced data analytics. Among its customers are Nine West, PLV Shoes, and Rocketdog.
Management expects the integration of Findify’s proprietary technology to increase monetization and propel revenue growth in both cannabis and hardware sales. In addition to anticipated growth in Namaste’s core business, the Company will allocate resources to expand on Findify’s existing platform and expects this to result in increased EBITDA by the end of 2019. Namaste also anticipates accelerating patient growth through its wholly owned subsidiary and Canada’s first fully-compliant online patient portal, NamasteMD Inc. (“NamasteMD†or “NamasteMD.comâ€). By implementing Findify’s technology in applications of patient acquisition, conversion rates, order value and customer retention, the Company expects to reach 50,000 medical cannabis patients by the end of 2018 and up to 100,000 by the end of 2019.
Findify’s platform which is used by leading e-commerce websites, including Namaste, uses proprietary real-time machine learning algorithms to build unique user profiles, and deliver a personalized experience for each user. The platform continuously learns from user behavior to automatically improve search results, recommendations, and product landing pages, displaying the most relevant products at any given time. It identifies product trends and, in combination with an analysis of unique customer behavior, ranks products in a way to optimize revenue, conversion rates and average order value. Based on the Bank of Canada’s exchange rate on May 1, 2018, Findify’s annual 2017 revenue was $503,170 and its first quarter 2018 revenue was $198,211.
Key terms of the Acquisition:
- Namaste will acquire all issued and outstanding shares of Findify in exchange for:
- US $2,000,000 in cash to be paid upon the closing date of the transaction.
- US $10,000,000 to be paid in common shares of Namaste at a mutually agreed price of C$1.80 per common share.
Key designated employees of Findify will be remaining with the company after the completion of the acquisition.
The acquisition of Findify brings an incredible amount of value to the Company in applications related to the online retail of medical cannabis. Namaste recognizes this as a unique opportunity to offer medical cannabis patients an even more personalized experience. The acquisition of Findify will reinforce Namaste’s goal of becoming the global leader in cannabis technology solutions by further expanding its innovative e-commerce platform and enhancing the user experience for cannabis patients globally.
In addition, the acquisition of Findify creates a new revenue stream for the Company in the field of artificial intelligence and data analytics. Namaste will continue to operate and expand on Findify’s existing platform and client portfolio. Namaste anticipates rapid expansion of its technology licensing business.
Management Commentary
Meni Morim, Founder and CEO of Findify comments: “The Findify team is very excited to join the Namaste family, and take part in revolutionizing the online cannabis domain. The team brings years of experience, having built a unique machine learning platform that leverages user behavior, to deliver a personalized e-commerce experience across touchpoints, with a focus on search & discovery. We believe that Namaste’s strong positioning in the market will enable us to take advantage of this technology in the best possible way, and deliver immediate value to customers and shareholders – by buildings the world’s first fully integrated A.I. platform for cannabis.
Having built a relationship with Namaste as a client over the past two years, we found that we share many of the same core values, work ethic, and passion for building products that people love. We’re confident that the merging of our teams will enable us to continue innovating in this fast-paced, growing industry.â€
Laurens Feenstra, Director of Namaste, an A.I. expert, and Product Manager for Google Waymo comments: “I am super excited for the talented team of Findify to join Namaste! Their leading machine learning models have already made Namaste much better at recommending the right products to our customers. And, even more importantly, we are thrilled to apply their deep A.I. expertise to cannabis. There are approximately 800 identified strains of cannabis each with hundreds of active ingredients, meaning each plant works differently for each person. Understanding which plant works for whom will be key in helping cannabis benefit everyone.â€
Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to announce the acquisition of Findify. This is a very exciting opportunity for Namaste to forge new ground in the cannabis industry by introducing what we believe to be the most innovative technology for on-site personalization. Moving forward we believe global cannabis patients will demand a more customized online experience, as products and services in the cannabis industry continue to grow exponentially. Having worked with Findify as a client, we have witnessed excellent results through the implementation of their technology and believe strongly in the quality of their management team. Based on the success we have seen in the utilization of similar technology in other industries, we are extremely excited and optimistic to become the first company to introduce this incredible technology into the cannabis market and further enhance the online experience for cannabis patients.
Our vision for the Company in becoming a global leader in medical cannabis technology is evident from the addition of our new board members coming from Google and SpaceX, industry leaders in the areas of machine learning and A.I. that chose to join Namaste’s team. Furthermore, this acquisition represents a major milestone for Namaste in solidifying itself as one of the most innovative technology companies in the cannabis industry.â€
About Findify AB
Findify is a leader in e-commerce machine learning applications, with over 1200 customers in more than 60 countries around the world. Findify has developed a unique machine learning core, that leverages user behaviour, to personalize online experiences in real-time. Findify’s machine learning technology has been proven to deliver up to 27% uplift in conversion rate, and up to 30% uplift in revenue per user.
Findify is an official Shopify Plus Technology Partner, recognized as a “Best-In-Class Solution†for modern, rapidly growing e-Commerce businesses.
About Namaste Technologies Inc.
Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.
On behalf of the Board of Directors
“Sean Dollingerâ€
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]
Further information on Namaste and its products can be accessed through the links below:
namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au
Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.
The medical #marijuana industry is about to get much bigger, CannTrust CEO says $N.ca $NXTTF $TBP.ca $MCOA $ACB.ca $HIP.ca $WEED.ca $CMED.ca
- The ramp up in Canada’s cannabis sector is ongoing
- Industry estimates of sales eventually adding up to between $5 and $8 billion a year
- By comparison, Canada produces a little under $3 billion of beer a year and about $1 billion in tobacco products.
April 19, 2018 By Jayson MacLean
Eric Paul
While all eyes are on the launch date for recreational cannabis in Canada —said to come in either late summer or early fall— the medical side of the equation should be getting the attention, as well, because it’s about to get much bigger, says Eric Paul, CEO of licensed producer CannTrust Holdings (TSX:TRST).
The ramp up in Canada’s cannabis sector is ongoing, with industry estimates of sales eventually adding up to between $5 and $8 billion a year. That’s substantial, since by comparison, Canada produces a little under $3 billion of beer a year and about $1 billion in tobacco products.
But while the rec market is getting all the focus, the medical marijuana industry both at home and abroad should be getting its props, since it’s growing by leaps and bounds.
“We’ve been astounded by the growth of the medical marijuana industry in Canada,†Eric Paul, CEO of CannTrust Holdings, tells BNN.
“Roughly ten or 12 per cent of the 80,000 doctors across Canada who could prescribe are prescribing [cannabis], and I would say we’re gaining on that for a number of reasons,†says Paul. “The first being the opiate crisis where doctors are looking for cannabis as a potential first-line therapy for pain management. The second thing is that there is more research coming out; we’re about to announce a couple of major research projects in Canada and one is a major pain management study. As these research projects produce their end result, more doctors are looking at cannabis as an alternate therapy for chronically ill people.â€
Statistics Canada has reported that between April and December of last year, the number of clients registered under its Access to Cannabis for Medical Purposes Regulations (ACMPR) has gone from 174,503 to 269,502.
Paul says that CannTrust itself has a 40,000-strong patient base and is looking to jump to 100,000 in 12 months time.
“We’ve had a major expansion in Niagara: a 430,000 sq. ft. state of the art greenhouse which is up and running,†says Paul. “We believe that with that capacity and with the nature of that facility, we’ll be able to supply our current customer demand in the medical market and have sufficient capacity to handle the first generation of recreational demand.â€
But aside from Canada’s own growing medical market, the international market is poised to take off in countries like Germany and Australia, and many of the top licensed producers in Canada are now lining up deals outside of Canada.
In March, CannTrust announced that it has entered into a joint venture agreement with a Danish company to grow and sell medical cannabis.
“The industry is globalizing much faster than any of us expected,†says Paul.
“Various countries are going into medical legislation and Denmark is one of those countries that have announced that we’re fully licensed there, we’ll be building a facility there,†he said. “In that country, the government has decided to fund the cost of it for the consumer, via prescription, and they’re willing to fund 100 per cent for people with palliative or end-of-life care and 50 per cent for chronic illness. That will allow those industries to quickly garner market share. Germany is a similar kind of situation and also Australia.â€
Source: https://www.cantechletter.com/2018/04/the-medical-marijuana-industry-is-about-to-get-much-bigger-canntrust-ceo-says/
Namaste $N.ca Announces Canada’s First Large-Scale National Prospective Observational Study to Observe the Impact of Medical #Cannabis Use for Anxiety Treatment $ACB.ca $HIP.ca $WEED.ca $CMED.ca
- Initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants
- One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety
VANCOUVER, British Columbia, April 04, 2018 – Namaste Technologies Inc. (“Namaste†or the “Companyâ€) (CSE:N) (FRANKFURT: M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants. One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety. Namaste is also interested in determining the safety profile of patients using medical cannabis, and whether strain and dose of medical cannabis may impact patient reductions in anxiety ratings. The study will be available to all Canadians and will be conducted under the following conditions:
- Prospective patients must be over 25 years of age.
- Patients must score 8 or above Hospital Anxiety and Depression Scale (HADS).
- The study will span over a 3-month period for each registered patient.
- The study will be submitted for approval to the Veritas Independent Review Board (IRB) prior to commencement.
- The primary investigator in the study is a nurse practitioner.
- Patients can self-refer into the study (without referral through a doctor or specialist).
Namaste plans to offer this study to its patients which are registered under the Company’s wholly-owned subsidiary and virtual patient platform, NamasteMD Inc. (“NamasteMDâ€). Patients suffering from anxiety under the terms outlined above may participate in the study. This study is the first large-scale anxiety study in the nation, establishing Namaste as an innovator in research related to anxiety and cannabis. This is also the first national study where the primary investigator is a nurse practitioner. The Company intends to conduct similar studies in various areas where patients can benefit from the use of medical cannabis. The data collected from the study is valuable for the Company as well as the industry as a whole. The study may be published in peer-reviewed research journals and other medical publications.
For more information on this study please email [email protected]
Management Commentary
Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have initiated this study with the help of our partners at O-Cannabis. As many people in Canada suffer from varying forms of anxiety, we believe that many of these patients can benefit from the use of medical cannabis instead of prescription pharmaceutical drugs. We hope this study will provide very valuable information for Namaste and for the industry. We encourage qualifying patients to participate and look forward to seeing the results. We plan to undertake additional studies to bring awareness and a better understanding of how medical cannabis can benefit Canadians. We believe that these studies will help Namaste by attracting a larger base of patients and help solidify Namaste’s position as a leader in the Canadian medical cannabis industry.â€
About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.
On behalf of the Board of Directors
“Sean Dollingerâ€
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]
Further information on the Company and its products can be accessed through the links below:
NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca
FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.
#Marijuana stocks just got less risky, GMP Securities says $N.ca $NXTTF.ca $TBP.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca
- Recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities
- Canada is poised to be an global leader in the cannabis space
- This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana
- bill passed 44 to 29
March 25, 2018 By Jayson MacLean
Canada’s still-developing cannabis sector has seen its share of fortunes won and lost over the past year, with stock prices skyrocketing in a matter of weeks over December and January, only to pull back considerably in the time since.
But recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities, who says Canada is poised to be an global leader in the cannabis space.
This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana. Although the vote was predicted to be tight, as some senators in favour of the legislation were out of Ottawa on committee work and Conservative senators promising to vote en masse against, the bill nevertheless passed 44 to 29.
That bodes well for the bill, says Landry, who projects a late summer/early fall opening up of the rec cannabis market.
“[The Senate vote] provides a positive read-through in our view for the potential outcome of the final third reading vote, as the majority of the Independent Senators Group appear to be aligned with the Liberals,†Landry said in a note to clients on Friday. “In a 3rd reading scenario where all Liberals and Conservatives vote for and against Bill C-45 respectively, this would suggest ~73 per cent of independents (versus 95 per cent at second reading) would need to vote in favour for Bill C-45 to become law.â€
As well, this past week Health Canada released its fourth quarter 2017 data on medical marijuana use, finding that patient registrations were up 14 per cent on the quarter to 269,502, while total volume of medical cannabis grew around 10 percent on the quarter and around 34 per cent year-over-year, the best growth rate over the past three quarters, says Landry.
Also coming from Health Canada were summary results from public consultations on the new cannabis regulations, held during a 60-day period starting this past November. The consultations drew in approximately 4,000 responses, covering all aspects of the proposed regulations including licensing and permits, security clearance and cannabis tracking, product packaging and labelling and the medical use of cannabis.
Some notable results include strong support from respondents for a quick roll-out on regulations regarding cannabis edibles along with majority support for the government’s plans concerning licensing and product labelling and plain packaging.
Landry says that going forward the report should feed into guidance and regulations for industry participants. On the issue of product labelling, the analyst says that Health Canada’s push for plain packaging could make it “difficult for licensed producers to differentiate their brands on the basis of packaging, however advertising rules are not expected to be more restrictive than those for tobacco,†Landry says.
In all, Landry sees the ramped up medical market and the maturing regulatory landscape to be a win for Canadian companies, who now have a head start over the competition when it comes to the industrial production of cannabis within a tightly regulated environment.
Landry says that having LPs required to deliver secure and stable production has “led Canadian licensed producers to build pharmaceutical grade production facilities, develop solid cultivation know-how and create a large bank of genetics,†he says. “Combined with well capitalized balance sheets, we believe that Canadian LPs are well positioned to become global leaders in the cannabis sector.â€
Source: https://www.cantechletter.com/2018/03/marijuana-stocks-just-got-less-risky-gmp-securities-says/
Namaste $N.ca $NXTTF Announces LOI With Inolife R&D to Conduct a Research Study to Evaluate Needle-Free Injection Technologies for Medical Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca
- Signed a non-binding LOI with Inolife R&D Inc.
- To initiate a research study to evaluate applications for Inolife’s proprietary needle-free injectors in the medical cannabis industry
VANCOUVER, British Columbia, March 12, 2018 – Namaste Technologies Inc. (“Namaste†or the “Companyâ€) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has signed a non-binding LOI with Inolife R&D Inc. (“Inolifeâ€), whereby Namaste and Inolife will negotiate the terms of a definitive agreement (the “Agreementâ€) to initiate a research study to evaluate applications for Inolife’s proprietary needle-free injectors in the medical cannabis industry. Under the terms of the LOI and proposed Agreement, Namaste will hold exclusive rights to research and distribute Inolife’s needle-free injection technologies for applications in the cannabis industry. Namaste will also participate in Inolife’s anticipated private placement by acquiring up to 10% of the shares issued under the offering. Inolife will also provide Namaste with the right to acquire up to an additional 10% of the shares issued under the offering at the same price. Additionally, Namaste will purchase up to 10% of the shares issued in connection with Inolife’s go-public transaction for approximately $250,000. Namaste believes that Inolife’s needle-free technologies could revolutionize dosage and administration of cannabis for medical purposes.
The LOI and proposed Agreement represent a strategic initiative for Namaste’s continued effort to offer innovative products to the medical cannabis market. Namaste believes that Inolife’s technology provides the most accurate and efficient method for dosing with medical cannabis. Namaste expects to work within Health Canada’s current and future cannabis regulations, when proceeding towards commercialization of pre-filled needle-free syringes. Namaste expects to commercialize the pre-filled needle-free syringes through its wholly owned subsidiary and late-stage applicant under Access to Cannabis for Medical Purposes Regulations (“ACMPRâ€), Cannmart Inc. The Company also expects to engage with Canadian ACMPR medical cannabis producers to co-brand medical cannabis oil, to be sold and used for applications with Inolife’s technology.
Key Terms of the LOI
- Namaste will initiate a research study to determine the viability to use Inolife’s needle-free injectors for medical cannabis.
- Namaste will bear all costs for research and development.
- Namaste will participate for up to 10% of Inolife’s anticipated private placement and go-public transaction.
- Namaste will have exclusive rights to distribute Inolife’s products for the purposes of use with medical cannabis.
- Both parties agree to a 30-day period from the execution date of the LOI to negotiate terms of a definitive agreement and establish a protocol to proceed with a research study.
Management Commentary
Michael Wright, President and CEO of Inolife comments, “We’re very excited about the proposed partnership with Namaste. We feel that Namaste is best positioned to deliver on our strategic plan to become an innovator of delivery systems for the medical cannabis industry. We’re pleased to be the first company, in partnership with Namaste, to explore needle-free device technology in the context of medical cannabis delivery.â€
Sean Dollinger, President and CEO of Namaste comments, “We are very pleased to announce this LOI and our expectation of providing research and development of this innovative technology for applications with medical cannabis. We believe that Inolife’s technology could provide the most efficient and accurate method for dosing with medical cannabis. We see a massive opportunity to revolutionize the industry by bringing this exciting technology to the medical cannabis market. We’re delighted to see that industry-leading companies like Inolife are recognizing Namaste for its value in its database, platform and brand.â€
About Inolife R&D Inc.
Inolife R&D Inc. is an emerging specialty medical device company focused on developing and commercializing self-administered medical products using novel drug delivery technologies. The company was founded to take advantage of novel techniques of liquid jet and ballistics-based epidermal drug injection that we believe will improve a patient’s quality of life by making medicines easier to self-administer, work better, and remove the anxiety and inconvenience associated with hypodermic needle injections.
About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.
On behalf of the Board of Directors,
“Sean Dollingerâ€
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]
Further information on Namaste and its products can be accessed through the links below:
namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au
For more information about Inolife R&D Inc. and its products please visit inolifesciences.com
Michael Wright
President, CEO
Direct: 1-866-834-3777
Email: [email protected]
Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.
Namaste $N.ca Announces February 2018 Sales of C$1.37M Representing a 146% Year-Over-Year Increase and Provides Update on #NamasteMD $ACB.ca $HIP.ca $WEED.ca $CMED.ca
- February 2018 total unaudited net revenue C$1,370,442
- 146% revenue increase in February 2018 vs. February 2017
VANCOUVER, British Columbia, March 07, 2018 – Namaste Technologies Inc. (“Namaste†or the “Companyâ€) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce February 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,370,442, representing a 146% revenue increase in February 2018 compared with February 2017. February is a historically low month for sales and as such, the Company is pleased with these results. Management anticipates these year-on-year growth trends to continue as the Canadian market moves towards cannabis legalization and the Company executes its strategy to expand sales in emerging markets.
The table below outlines gross sales of Namaste’s major sites and includes site traffic, conversion rates, total number of orders per site and average online basket price.
In addition to announcing its February sales, the Company is pleased to provide an update on its progress with Namaste’s medical cannabis telemedicine application, NamasteMD. During the month of February, management initiated a soft-launch of NamasteMD, which is now available on Apple and Google Android devices. The Company is pleased with initial results, having over 3,000 downloads with a 5-star rating on the Apple Store and a 4.9-star rating on Google Android. The Company, through its soft-launch of NamasteMD has also acquired 375 medical cannabis patients. The Company is now focusing on streamlining the patient acquisition process and further developing the platform. Management anticipates substantial growth in patient acquisition rates for March following a full launch of NamasteMD across the Company’s Canadian platform.
Management Commentary
Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to be seeing the positive trend of monthly sales increases year-over-year. With the Cannmart license pending approval, we are very encouraged to see our hardware business growing, which should have a direct impact on our ability to expand our e-commerce platform to include the sale of cannabis products and shift our focus on aggressive acquisition of patients via NamasteMD. While the soft-launch of NamasteMD has been a success, we feel that obtaining our sales license should substantially increase our ability to convert downloaded users into patients. Our ability to provide patients with an all-inclusive e-commerce marketplace of cannabis products and services in the near term should serve to significantly increase our market share moving forward.â€
About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.
On behalf of the Board of Directors
“Sean Dollingerâ€
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]
Further information on Namaste and its products can be accessed through the links below:
namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au
Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.
Tetra Bio-Pharma $TBP.ca Announces Closing of Bought Deal Financing $ACB.ca $HIP.ca $WEED.ca $CMED.ca
- Closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriter’s over-allotment option
- Total of 11,500,000 units of the Corporation were sold at a price of $1.00 per Unit
OTTAWA, March 05, 2018 — Tetra Bio-Pharma Inc. (“Tetra†or the “Corporationâ€) (TSX-V:TBP) (OTCQB:TBPMF), is pleased to announce it has closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriter’s over-allotment option. A total of 11,500,000 units (the “Unitsâ€) of the Corporation were sold at a price of $1.00 per Unit, for aggregate gross proceeds of $11,500,00 (the “Offeringâ€).
Each Unit consisted of one common share of the Corporation and one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one common share of the Corporation at a price of $1.30 until March 5, 2021. The Offering was underwritten by Echelon Wealth Partners Inc.
The Corporation intends to use the net proceeds from the Offering to continue the development of its clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers, to repay indebtedness of the Corporation, and for working capital and general corporate purposes.
“We are extremely pleased to have worked with Echelon Wealth Partners in this financing . As we are about to initiate our Health Canada approved phase 3 registration trial for our lead drug candidate, PPP001, for late stage cancer patients, the proceeds from this Offering will enable Tetra to continue, and potentially accelerate some of the key development projects in our pipeline. This is another milestone in working towards becoming the first biopharmaceutical company in the world to get a smokable dried cannabis product approved as a prescription drug by Health Canada, the FDA and other regulatory agencies around the world,” stated Bernard Fortier, CEO of Tetra.
The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act“) or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.
This press release does not constitute an offer to sell or a solicitation of any offer to buy the securities in the United States, in any province or territory of Canada or in any other jurisdiction. There shall be no sale of the securities in any jurisdiction in which an offer to sell, a solicitation of an offer to buy or sale would be unlawful.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
For further information, please contact Tetra Bio-Pharma Inc.
Bernard Lessard, MBA, CPA, CMA
Chief Financial Officer
[email protected]
438 899 7575 ext.207
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, failure to obtain sufficient financing to execute the Corporation’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.